Comparative Pharmacology
Head-to-head clinical analysis: ANKTIVA versus REBIF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANKTIVA versus REBIF.
ANKTIVA vs REBIF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ANKTIVA is a live attenuated, nonpathogenic recombinant strain of Vibrio cholerae O1 (CVD 103-HgR) that colonizes the intestinal mucosa and elicits protective mucosal and systemic immune responses against V. cholerae, including production of vibriocidal and antitoxin antibodies.
Interferon beta-1a binds to type I interferon receptors, activating the JAK-STAT signaling pathway, which leads to expression of interferon-responsive genes. This results in modulation of immune responses, including reduction of pro-inflammatory cytokines, enhancement of anti-inflammatory cytokines, inhibition of T-cell activation and proliferation, and decreased blood-brain barrier permeability.
Intravesical instillation of 300 mg (25 mL) once weekly for 6 weeks, followed by maintenance therapy of 300 mg once monthly for 6 or 12 months.
Subcutaneous injection, 22 mcg (0.5 mL) or 44 mcg (0.5 mL) three times per week, at least 48 hours apart.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours; clinically, steady-state reached after 2-3 days
Terminal half-life approximately 50 hours (range 28-75 hours) after subcutaneous administration, supporting every-other-day dosing.
Renal: ~70% unchanged; fecal: ~30% as metabolites
Renal (primarily via glomerular filtration and catabolism) and hepatic metabolism; <5% excreted unchanged in urine.
Category C
Category C
Immunomodulator
Immunomodulator